Author: Andrew Celentano - Page 16 - Start Medical Product Development

Florida Cancer Specialists & Research Institute Contributes to Two Significant FDA Approvals Advancing Breast and Pancreatic Cancer Care

October 14, 2026

FORT MYERS, Fla., Oct. 14, 2026 /PRNewswire/ — Florida Cancer Specialists & Research Institute, LLC (FCS) is celebrating its pivotal role in the development of two recently approved targeted therapies that expand treatment options for patients with advanced breast and pancreatic cancers, underscoring the FCS’s longstanding commitment to advancing oncology research and expanding access to clinical trials.

Trial Demonstrates Feasibility of At-Home Subcutaneous Diuretic Therapy for Heart Failure-Associated Edema

October 14, 2026

BURLINGTON, Mass., Oct. 14, 2026 /PRNewswire/ — SQ Innovation today announced that results of the SUBCUT HF II trial of its product Lasix® ONYU have been published in the Journal of the American College of Cardiology (JACC)1, one of the leading peer-reviewed journals in cardiovascular medicine.

AI screening helps more people with diabetes access sight-saving eye care

October 13, 2026

People receiving AI-supported screening for diabetic retinopathy, a leading cause of blindness globally, were almost twice as likely to attend specialist follow-up appointments as those receiving standard screening, according to new research from the London School of Hygiene & Tropical Medicine (LSHTM).

How a common virus’s hijack of cell repair processes may promote cancer

October 13, 2026

Most people will become infected with Epstein-Barr virus, or EBV, at some point in their lives. In addition to being a common herpesvirus, EBV persists in its host for life as a “quiet” or latent infection.

Targeted radioactive therapy may help delay spread of recurrent prostate cancer

October 13, 2026

Adding the targeted radioactive drug 177Lu-PNT2002 to stereotactic body radiation therapy, or SBRT, may help keep recurrent prostate cancer under control longer than SBRT alone, according to new research led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.

AI tool reveals what attracts immune cells to tumors and what keeps them away

October 13, 2026

Researchers at The University of Texas MD Anderson Cancer Center and collaborating institutions in Texas developed an artificial intelligence (AI) model that helps explain how immune cells find their way to specific locations in the body and why they avoid others. The findings could help scientists better understand cancer, autoimmune diseases and treatment response.

Emotion-focused AI spots early signs of psychosis in youths from short speech samples

October 13, 2026

Nanyang Technological University, Singapore (NTU Singapore) and the Institute of Mental Health (IMH) have developed an artificial intelligence (AI) framework capable of identifying youths at high risk of psychosis from short samples of casual, spontaneous speech.

Continuously evolving cells help pancreatic cancer evade treatment and spread

October 13, 2026

An analysis of nearly half a million cells from dozens of patients’ tumors reveals how cancer cells continuously reshape their genetic makeup over time, enabling them to evade treatment for one of the deadliest forms of cancer.

One dose of protein-targeting CAR-T cells shrinks solid tumors in preclinical tests

October 13, 2026

CAR-T cell therapies have fundamentally transformed the treatment of several blood and lymph node cancers.

Two studies link elevated ear protein levels in blood to tinnitus

October 13, 2026

When Dr. Kourosh Parham conceived a first-of-its-kind blood test for tinnitus, he knew further research was needed to confirm a link between a unique ear protein and the common hearing disorder. To validate his theory, the professor of surgery at UConn Health (UCH), Division of Otolaryngology-Head & Neck Surgery, teamed up with fellow UCH physician-scientists to conduct two clinical trials.